XML 104 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Description of the Business (Details)
$ / shares in Units, $ in Thousands
1 Months Ended
Mar. 18, 2026
USD ($)
$ / shares
shares
Mar. 17, 2026
USD ($)
shares
Nov. 17, 2025
USD ($)
$ / shares
shares
Oct. 21, 2025
USD ($)
shares
Feb. 06, 2024
USD ($)
$ / shares
shares
Mar. 31, 2026
USD ($)
subsidiary
clinical-stageAsset
$ / shares
shares
Oct. 31, 2025
$ / shares
shares
Feb. 29, 2024
shares
Dec. 31, 2025
USD ($)
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Number of wholly owned subsidiaries | subsidiary           1      
Number of clinical-stage assets | clinical-stageAsset           7      
Accumulated deficit | $           $ 227,871     $ 201,634
Preferred stock conversion, number of common stock (in shares)               13,664,261  
IPO                  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares)         9,246,000        
Sale of stock, price per share (in dollars per share) | $ / shares         $ 16.00        
Sale of stock, consideration received on transaction | $         $ 133,000        
Number of shares called by warrants (in shares)         72,631        
Over-Allotment Option                  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares)         1,206,000        
Private Placement                  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Sale of stock, number of shares issued in transaction (in shares)   2,900,000   3,832,263   2,900,000 3,832,263    
Sale of stock, price per share (in dollars per share) | $ / shares           $ 20.00 $ 5.9140    
Sale of stock, consideration received on transaction | $   $ 114,900   $ 49,700          
Number of shares called by warrants (in shares)             4,622,251    
Pre-Funded Warrants                  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Number of shares called by warrants (in shares)   3,100,000   4,622,251   3,100,000      
K2 Healthventures LLC                  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]                  
Sale of stock, price per share (in dollars per share) | $ / shares $ 4.83   $ 4.83            
Sale of stock conversion of outstanding loan | $ $ 1,000   $ 4,000            
Stock issued during period (in shares) 207,215   828,860